Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

14
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
14

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

Transplantation and cellular therapy·2026
Same author

Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.

Transplantation and cellular therapy·2026
Same author

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.

Leukemia & lymphoma·2026
Same author

Current landscape and future directions for treatment of accelerated-phase and blast-phase myeloproliferative neoplasms.

Seminars in hematology·2026
Same author

Acute myeloid leukemia after myeloproliferative neoplasms: Real-world outcomes in the new treatment era in the United States.

Cancer·2026

Related Experiment Video

Updated: Oct 7, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

327

Azacitidine maintenance in AML post induction and posttransplant.

Jan Philipp Bewersdorf1, Thomas Prebet2, Lohith Gowda2

  • 1Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Current Opinion in Hematology
|January 11, 2022
PubMed
Summary

Oral azacitidine (CC-486) shows survival benefits as postremission therapy for acute myeloid leukemia (AML) patients ineligible for transplant. It also demonstrates safety and encouraging disease-free survival as maintenance therapy post-transplant.

More Related Videos

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.2K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

2.6K

Related Experiment Videos

Last Updated: Oct 7, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

327
Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.2K
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
06:28

Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis

Published on: November 10, 2023

2.6K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Acute myeloid leukemia (AML) relapse is a primary cause of mortality post-induction and allogeneic hematopoietic cell transplant (allo-HCT).
  • Prolonging remission duration while minimizing nonrelapse mortality is a critical unmet need in AML patient care.

Purpose of the Study:

  • To review the efficacy and safety of CC-486 (oral azacitidine) as postremission therapy (PRT) and maintenance therapy in AML patients.
  • To explore the potential of hypomethylating agents in improving outcomes for AML patients.

Main Methods:

  • Review of findings from the QUAZAR AML-001 study evaluating CC-486 as PRT.
  • Analysis of CC-486 use as maintenance therapy post-allo-HCT.
  • Consideration of recent trial data and meta-analyses on azacitidine in AML post-transplant.

Main Results:

  • CC-486 demonstrated an overall survival (OS) benefit in AML patients in CR1 ineligible for allo-HCT.
  • CC-486 showed acceptable safety and encouraging disease-free survival (DFS) as maintenance therapy post-allo-HCT.
  • Conflicting results from trials highlight the need for refined risk stratification to identify optimal patient subsets.

Conclusions:

  • Postremission therapy with hypomethylating agents like CC-486 is feasible and offers survival advantages in select AML populations.
  • Further understanding of azacitidine's epigenetic and immunomodulatory effects may enhance its role in future AML treatment strategies.